Cellectis boosts its coffers in revised off-the-shelf CAR-T deal with Servier
Years before the CAR-T therapies Kymriah and Yescarta hit the market, two French companies joined forces in a quest to bring off-the-shelf immunotherapies based on gene-edited allogeneic CAR-T cells to fruition.
Now, the players Cellectis and partner Servier have amended the terms of their collaboration, six years after they first inked a deal to co-develop Cellectis’ lead product candidate, UCART19, in addition to five other product candidates targeting solid tumors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
